FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Darvish Nissim
  2. Issuer Name and Ticker or Trading Symbol
Chemomab Therapeutics Ltd. [CMMB] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
C/O CHEMOMAB THERAPEUTICS LTD., KIRYAT ATIDIM, BUILDING 7		 3. Date of Earliest Transaction (Month/Day/Year)
06/14/2023
(Street)

TEL AVIV, L3 6158002		 4. If Amendment, Date Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4) 		7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
American Depositary Shares (1) (2)               1,200 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5) 		6. Date Exercisable and Expiration Date
(Month/Day/Year) 		7. Title and Amount of Underlying Securities
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4) 		10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4) 		11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Option to Purchase American Depositary Shares (1) (2) $ 1.7 06/14/2023   A   20,572     (3) 06/14/2033 American Depositary Shares (2) 20,572 $ 0 20,572 D  
Option to Purchase American Depositary Shares (1) (2) $ 1.62 03/16/2023   A   6,857     (4) 03/21/2033 American Depositary Shares (2) 6,857 $ 0 6,857 D  
Option to Purchase American Depositary Shares (1) (2) $ 3.53 03/07/2022   A   6,820     (5) 03/07/2032 American Depositary Shares (2) 6,820 $ 0 6,820 D  
Option to Purchase American Depositary Shares (1) (2) $ 27.26 04/19/2021   A   11,884     (6) 04/19/2031 American Depositary Shares (2) 11,884 $ 0 11,884 D  
Option to Purchase American Depositary Shares (1) (2) $ 0.8 10/28/2016   A   10,123     (7) 10/27/2017 American Depositary Shares (2) 10,123 $ 0 10,123 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Darvish Nissim
C/O CHEMOMAB THERAPEUTICS LTD.
KIRYAT ATIDIM, BUILDING 7
TEL AVIV, L3 6158002		   X      

Signatures

 /s/ Matthew Rudolph, Esq., Attorney-in-Fact for Nissim Darvish   07/05/2023
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) No transaction has been effected by the Reporting Person with respect to these securities, and they are being included in this Form 4 for informational purposes only.
(2) Each American Depositary Share (ADS) represents twenty (20) ordinary shares, no par value, of the Issuer.
(3) These options vest and become exercisable in equal monthly installments over a 36 month period, subject to the Reporting Person's continued service.
(4) These options were granted as per the annual grant of options to directors. These options vest and become exercisable in their entirety on March 16, 2024, subject to the Reporting Person's continued service.
(5) These options vested and became exercisable in their entirety on March 16, 2023. These options were granted as per the annual grant of options to directors.
(6) These options vest and become exercisable in equal monthly installments over a 36 month period commencing on March 16, 2021, subject to the Reporting Person's continued service.
(7) The options reported in this row have all vested and are exercisable as of the date hereof, subject to the Reporting Person's continued service.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.